Christopher Ray Aker - Net Worth and Insider Trading
Christopher Ray Aker Net Worth
The estimated net worth of Christopher Ray Aker is at least $16,190 dollars as of 2024-12-01. Christopher Ray Aker is the Sr. VP & General Counsel of Regulus Therapeutics Inc and owns about 10,056 shares of Regulus Therapeutics Inc (RGLS) stock worth over $16,190. Details can be seen in Christopher Ray Aker's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Ray Aker has not made any transactions after 2024-01-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Christopher Ray Aker
Christopher Ray Aker Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher Ray Aker owns 1 companies in total, including Regulus Therapeutics Inc (RGLS) .
Click here to see the complete history of Christopher Ray Aker’s form 4 insider trades.
Insider Ownership Summary of Christopher Ray Aker
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RGLS | Regulus Therapeutics Inc | 2024-01-18 | Sr. VP & General Counsel |
Christopher Ray Aker Latest Holdings Summary
Christopher Ray Aker currently owns a total of 1 stock. Christopher Ray Aker owns 10,056 shares of Regulus Therapeutics Inc (RGLS) as of January 18, 2024, with a value of $16,190.
Latest Holdings of Christopher Ray Aker
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RGLS | Regulus Therapeutics Inc | 2024-01-18 | 10,056 | 1.61 | 16,190 |
Holding Weightings of Christopher Ray Aker
Christopher Ray Aker Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher Ray Aker has made a total of 6 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Regulus Therapeutics Inc is the sale of 5,468 shares on January 18, 2024, which brought Christopher Ray Aker around $6,507.
Insider Trading History of Christopher Ray Aker
- 1
Christopher Ray Aker Trading Performance
Christopher Ray Aker Ownership Network
Christopher Ray Aker Owned Company Details
What does Regulus Therapeutics Inc do?
Who are the key executives at Regulus Therapeutics Inc?
Christopher Ray Aker is the Sr. VP & General Counsel of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Financial Officer Crispina Calsada , Chief Operating Officer Joseph P Hagan , and President & Head of R & D Preston Klassen .
Regulus Therapeutics Inc (RGLS) Insider Trades Summary
Over the past 18 months, Christopher Ray Aker made 1 insider transaction in Regulus Therapeutics Inc (RGLS) with a net sale of 5,468. Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net purchase of 4,000 shares made by Kathryn J Collier .
In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.
Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regulus Therapeutics Inc Insider Transactions
Christopher Ray Aker Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher Ray Aker. You might contact Christopher Ray Aker via mailing address: C/o Regulus Therapeutics Inc., 10614 Science Center Drive, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
